| |
|
|
|
|
|
 |
| |
|
½ÅÀÏÆ®·¹½º¿À¸¯½ºÈÌÆ®Ä°¼¿ TRES ORIX FORTE CAP. sinil
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
653801660
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
ºÐÈ«»ö ºÐ¸»ÀÌ µé¾îÀÖ´Â ÁÖȲ»öÀÇ °æÁúĸ½¶Á¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
120cap. |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 1.5¹Ð¸®±×·¥ |
120 ĸ½¶ |
8806538016603 |
8806538016610 |
|
|
| ÁÖ¼ººÐÄÚµå |
A49400ACH
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| ´ëÇ¥ÄÚµå |
8806538016603 |
| º¸°ü¹æ¹ý |
±â¹Ð¿ë±â,½Ç¿Âº¸°ü |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
½Ä¿åºÎÁø
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ 1ȸ 1ĸ½¶ 1ÀÏ 2ȸ 8Àϰ£ ½ÄÀü¿¡ º¹¿ëÇϰí ÀÌÈĺÎÅÍ´Â 1ȸ 2ĸ½¶, 1ÀÏ 2ȸ º¹¿ëÇÑ´Ù.
|
| ±Ý±â |
´ÙÀ½ ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¸» °Í.
1) ³ì³»Àå ȯÀÚ
2) ÀÌ ¾àÀÇ ¼ººÐ¿¡ °ú¹ÎÁõ ȯÀÚ
3) ¿äÀú·ùÀÇ ¼ÒÀÎÀÌ Àִ ȯÀÚ
4) °í·ÉÀÚ ¹× ¼è¾à ȯÀÚ
5) ½Å»ý¾Æ
|
| ½ÅÁßÅõ¿© |
´ÙÀ½ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÒ °Í.
Ȳ»ö5È£(¼±¼Â¿»·Î¿ì FCF, Sunset Yellow FCF) ÇÔÀ¯ Á¦Ç°ÀÎ °æ¿ì: ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
|
| ÀÌ»ó¹ÝÀÀ |
1) °ú¹Î¼º ȯÀÚ¿¡¼´Â Á¹À½ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) µå¹°°Ô µÎÅë, ±¸¿ª, ±¸°¥ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
MAOÀúÇØÁ¦ ¹× ±âŸ ÁßÃ߽Űæ¾ïÁ¦Á¦¿Í º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù.
|
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
±â¹Ð¿ë±â,½Ç¿Âº¸°ü |
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Cyproheptadine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Cyproheptadine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.
L-lysine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Proteins of the herpes simplex virus are rich in L-arginine, and tissue culture studies indicate an enhancing effect on viral replication when the amino acid ratio of L-arginine to L-lysine is high in the tissue culture media. When the ratio of L-lysine to L-arginine is high, viral replication and the cytopathogenicity of herpes simplex virus have been found to be inhibited. L-lysine may facilitate the absorption of calcium from the small intestine.
|
| Pharmacology |
Cyproheptadine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Cyproheptadine is a piperidine antihistamine. Unlike other antihistamines, this drug also antagonizes serotonin receptors. This action makes Cyproheptadine useful in conditions such as vascular headache and anorexia. Cyproheptadine does not prevent the release of histamine but rather competes with free histamine for binding at HA-receptor sites. Cyproheptadine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. Most antihistamines possess significant anticholinergic properties, but Cyproheptadine exerts only weak anticholinergic actions. Blockade of central muscarinic receptors appears to account for Cyproheptadine's antiemetic effects, although the exact mechanism is unknown. Cyproheptadine also competes with serotonin at receptor sites in smooth muscle in the intestines and other locations. Antagonism of serotonin on the appetite center of the hypothalamus may account for Cyproheptadine's ability to stimulate appetite. Cyproheptadine also has been used to counter vascular headaches, which many believe are caused by changes in serotonin activity, however it is unclear how Cyproheptadine exerts a beneficial effect on this condition.
L-lysine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Insures the adequate absorption of calcium; helps form collagen ( which makes up bone cartilage & connective tissues); aids in the production of antibodies, hormones & enzymes. Recent studies have shown that Lysine may be effective against herpes by improving the balance of nutrients that reduce viral growth. A deficiency may result in tiredness, inability to concentrate, irritability, bloodshot eyes, retarded growth, hair loss, anemia & reproductive problems.
|
| Metabolism |
Cyproheptadine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
L-lysine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Cyproheptadine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 96 to 99%
|
| Half-life |
Cyproheptadine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Cyproheptadine¿¡ ´ëÇÑ Absorption Á¤º¸ Well absorbed after oral administration.
L-lysine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed from the lumen of the small intestine into the enterocytes by an active transport process
|
| Pharmacokinetics |
Cyproheptadine orotateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´ë»ç : °ÅÀÇ ´ëºÎºÐÀÌ ´ë»ç¹ÞÀ½
- ¹Ý°¨±â : 20-24 ½Ã°£
- ¼Ò½Ç : 50% ÀÌ»óÀÌ ½Å¹è¼³ (ÁÖ·Î ´ë»çü), ¾à 25%°¡ ´ëº¯À¸·Î ¼Ò½ÇµÊ
CobamamideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö :
- °æ±¸ Åõ¿©½Ã ¼ÒÀå ¿øÀ§ºÎ·ÎºÎÅÍ ºÒ±ÔÄ¢ÀûÀ¸·Î Èí¼öµÈ´Ù.
- ´Éµ¿ Èí¼ö¿¡´Â IF¿ÍÀÇ º¹ÇÕü Çü¼ºÀÌ ÇʼöÀûÀ̸ç, Àå°üº®À» ÅëÇØ ¼öµ¿ Èí¼öµµ °¡´ÉÇÏ´Ù.
- À§, ȸÀå¿¡ ±¸Á¶Àû ¼Õ»óÀ̳ª ±â´ÉÀû ¼Õ»óÀÌ ÀÖ´Â °æ¿ì Èí¼ö°¡ °¨¼ÒÇÑ´Ù.
- ºÐÆ÷ :
- À§¿¡¼ À§Á¡¸·¿¡ ÀÇÇØ ºÐºñµÇ´Â ´ç´Ü¹éÀÎ IF (intrinsic factor)¿¡ °áÇÕÇÑ´Ù.
- Àå°ü Á¡¸·¼¼Æ÷ ³»¿¡¼ vitamin B12-IF º¹ÇÕü·ÎºÎÅÍ vitamin B12°¡ À¯¸®µÈ ÈÄ, Ç÷¾× ³»¿¡¼ ÁַΠƯÀÌÀûÀÎ ¥â-globulin ¼ö¼Û´Ü¹éÁúÀÎ transcobalamin II¿Í °áÇÕÇÑ´Ù.
- °£, °ñ¼ö ¹× ŹÝÀ» Æ÷ÇÔÇÑ ±âŸ Á¶Á÷À¸·Î ºÐÆ÷Çϸç, ÁÖ·Î °£ (50-90%)¿¡ ÀúÀåµÈ´Ù.
- ´Ü¹é°áÇÕ : ÁÖ·Î transcobalamin II¿Í °áÇÕÇϸç, ¼Ò·®Àº transcobalamin I (¥á-glycoproteinÀÇ ÀÏÁ¾) ¹× transcobalamin III (inter-¥á-glycoproteinÀÇ ÀÏÁ¾)°ú °áÇÕÇÑ´Ù.
- ´ë»ç : Àå°£¼øÈ¯
- ¼Ò½Ç :
- Vitamin B12¸¦ Åõ¿©¹Þ°í ÀÖÁö ¾Ê´Â Á¤»óÀÎ : ¸¹Àº ¾çÀÌ ´ãÁó ¹è¼³ ÈÄ Àå°£¼øÈ¯ÇÑ´Ù.
- ÀÏÀÏ turnover rate : ü³» ÃÑÀúÀå·®ÀÇ 0.05-0.2% (¹üÀ§ : 0.4-8 ¥ìg)
- ÀÏÀÏ ½Å¹è¼³·®Àº ´ë°³ 0.25 ¥ìg ÀÌÇÏ
- Vitamin B12¸¦ Åõ¿©¹Þ´Â °æ¿ì : 0.1-1 mg ±ÙÀ°ÁÖ»ç ¶Ç´Â Á¤¸ÆÁÖ»ç ÈÄ 48½Ã°£ À̳»¿¡ 50-90%°¡ ½Å¹è¼³µÈ´Ù.
|
| Biotransformation |
Cyproheptadine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic (cytochrome P-450 system) and some renal.
L-lysine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
|
| Toxicity |
Cyproheptadine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
L-lysine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Cyproheptadine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Donepezil Possible antagonism of actionFluoxetine Possible antagonism of actionGalantamine Possible antagonism of actionMetyrapone This combination renders test invalidRivastigmine Possible antagonism of action
L-lysine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Cyproheptadine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food.Avoid alcohol.
|
| Drug Target |
[Drug Target]
|
| Description |
Cyproheptadine¿¡ ´ëÇÑ Description Á¤º¸ A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. [PubChem]
L-lysine¿¡ ´ëÇÑ Description Á¤º¸ L-Lysine (abbreviated as Lys or K)[1] is an α-amino acid with the chemical formula HO2CCH(NH2)(CH2)4NH2. This amino acid is an essential amino acid, which means that humans cannot synthesize it. Its codons are AAA and AAG.L-Lysine is a base, as are arginine and histidine. The ε-amino group often participates in hydrogen bonding and as a general base in catalysis. Common posttranslational modifications include methylation of the ε-amino group, giving methyl-, dimethyl-, and trimethyllysine. The latter occurs in calmodulin. Other posttranslational modifications include acetylation. Collagen contains hydroxylysine which is derived from lysine by lysyl hydroxylase. O-Glycosylation of lysine residues in the endoplasmic reticulum or Golgi apparatus is used to mark certain proteins for secretion from the cell.
|
| Drug Category |
Cyproheptadine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Allergic AgentsAntihistamine derivativesAntipruriticsGastrointestinal AgentsHistamine H1 AntagonistsSerotonin Antagonists
L-lysine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementEssential Amino AcidsMicronutrient
|
| Smiles String Canonical |
Cyproheptadine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12
L-lysine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NCCCCC(N)C(O)=O
|
| Smiles String Isomeric |
Cyproheptadine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN1CC\C(CC1)=C1\C2=CC=CC=C2C=CC2=CC=CC=C12
L-lysine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NCCCC[C@H](N)C(O)=O
|
| InChI Identifier |
Cyproheptadine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3
L-lysine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1/f/h9H
|
| Chemical IUPAC Name |
Cyproheptadine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ Not Available
L-lysine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S)-2,6-diaminohexanoic acid
|
| Drug-Induced Toxicity Related Proteins |
LYSINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Tamm-Horsfall protein Drug:Lysine Toxicity:persisting acute renal failure . [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|